Drug Trial Radar · NCT06661694
A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 28, 2025
Primary completion
Sep 8, 2025
Study completion Sep 9, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the amount of mevrometostat available from four different tablet formulations, taken with food, in healthy adult participants. This study is seeking male or female participants who: * are 18 years or older * are healthy as decided by medical tests. * have a Body mass index (BMI) of 16 to 32 kilogram per meter squared * a total body weight of more than 50 kilograms (110 pounds). All participants will take part in 4 study periods to receive 4 different treatments, which are assigned in a random order. There will also be a 5-day gap between each study period. This is done so that the medicine is passed out of the body before the start of the next period. Each treatment consists of a single dose of mevrometostat (PF-06821497), and the treatments differ only by tablet formulation. How the medicine is processed in the body will be studied after giving the medicines to the participants. This will be done by collecting blood samples after giving each of these tablets. The results will be used to see the effect of tablet formulation on the amount of mevrometostat (PF-06821497) available in the blood of the participants. Participants will be in the study for about 12 weeks.
Conditions
- Healthy
Interventions
Treatment ADrug
Single 875 mg dose of mevrometostat standard tablet formulation
Treatment BDrug
Single 875 mg dose of mevrometostat alternative tablet formulation
Treatment CDrug
Single 875 mg dose of mevrometostat alternative tablet formulation
Treatment DDrug
Single 875 mg dose of mevrometostat alternative tablet formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of Mevrometostat (Formulation 1)Time frame: Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
- Maximum Observed Plasma Concentration (Cmax) of Mevrometostat (Formulation 2)Time frame: Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Mevrometostat (Formulation 1)Time frame: Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Mevrometostat (Formulation 2)Time frame: Period 1-4: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hour(s) post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.